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a  b  s  t  r  a  c  t
Relapsing polychondritis is an uncommon, immune-mediated condition characterized by
episodes of inﬂammation of cartilaginous structures, especially the ears, nose, joints and
respiratory tract. RP also affects proteoglycan-rich structures such as the eyes, heart, blood
vessels and inner ear. Around one third of cases are associated with other diseases such as
vasculitides, connective tissue diseases or myelodysplastic syndrome. Disorders of the inner
ear occur in 40–50% of patients. Profound hearing loss is rare. The aim of this study was to
describe the case of a patient with relapsing polychondritis associated with severe bilateral
hearing loss and clinical manifestations of systemic vasculitis. This study reinforces the
importance of an early diagnosis and immediate treatment in case of severe manifestations
of  the disease.
© 2014 Elsevier Editora Ltda. All rights reserved.
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r  e  s  u  m  o
Policondrite recidivante é uma condic¸ão rara, imunomediada, caracterizada por episódios
de  inﬂamac¸ão de estruturas cartilaginosas, principalmente orelhas, nariz, articulac¸ões e
sistema respiratório. Acomete também estruturas ricas em proteoglicanos como olhos,
corac¸ão,  vasos sanguíneos e ouvido interno. Em torno de 1/3 dos casos apresentam
associac¸ão  com outras doenc¸as como vasculites sistêmicas, doenc¸as do tecido conectivo ou
síndrome mielodisplásica. Desordens do ouvido interno ocorrem em 40%-50% dos pacientes.
Perda auditiva profunda é rara. O objetivo do estudo foi descrever o caso de uma pacientecom diagnóstico de policondrite recidivante associado à perda auditiva severa bilateral e
manifestac¸ões clínicas de vasculite sistêmica. Este trabalho reforc¸a a importância do diag-
nóstico precoce e do tratamento imediato em caso de manifestac¸ões severas da doenc¸a.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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Fig. 2 – Hyaline cartilage (pinna) containing numerous
inﬂammatory cells with matrix degeneration.
(Hematoxylin–eosin – 100×). Inset: evidence of inﬁltrater e v b r a s r e u m a t o l
ntroduction
elapsing polychondritis (RP) is a rare, immune-mediated
ondition characterized by episodes of inﬂammation of car-
ilaginous structures, especially the ears, nose, joints and
espiratory system. It also affects proteoglycan-rich structures
uch as the eyes, heart, blood vessels and inner ear. The dis-
ase was ﬁrst described in 1923 by Jaksch-Wartenhorst, who
amed the disease policondropathy. Pearson et al. introduced
he term polychondritis in 1960.1 The condition affects men
nd women equally and can be seen in all races. Its peak
ncidence is between 40 and 60 years.2
The etiology of RP is unknown. The genetic predisposition
s suggested by the association with leukocyte antigen HLA-
R4.3 There is evidence for the emergence of autoimmunity,
oth humoral and cellular, against cartilage matrix compo-
ents such as collagen types II, IX, XI and matriline-1.2
We  report the case of RP associated with severe hearing
oss and vasculitic skin lesions.
ase  report
MD,  31 years old, female, with an everyday fever for
wo months, associated with chills, asthenia, polyarthritis,
rogressive bilateral hearing loss, tinnitus and episodes of
izziness. A month ago, her case evolved with the appearance
f skin lesions on the hands and lower limbs, bilateral edema
n the eyelids and ears, and a continuous pain in the distal
egion of 2nd right ﬁnger.
A physical examination revealed arthritis in wrists, elbows,
nkles and proximal interphalangeal joints bilaterally. Her
kin lesions were characterized by papules, pustules and
urplish plaques on the hands, feet and anterior legs. In
er oropharynx, aphthous ulcers were observed. It was also
oticed a lobe-sparing swelling and pain on palpation in her
innae, and bilateral conjunctival edema and erythema. The
istal region of 2nd right ﬁnger exhibited a ﬁxed painful
yanosis, associated with lower temperatures (Fig. 1).
Complementary tests showed normocytic and nor-
ochromic  anemia (hemoglobin 7.9 g/dL), leukocytosis of
6,000 mm3 without shift, and elevation of inﬂammatory
arkers: C-reactive protein (CRP 196 mg/L), erythrocyte
ig. 1 – Left, vasculitic injury in 2nd right chirodactyl. Right,
dema in the pinna, sparing the ear lobe.with numerous neutrophils, in association with
lymphocytes and histiocytes (400×).
sedimentation rate (ESR, 45 mm within 1 h). Serology for
hepatitis B and C and HIV were negative, and the presence
of autoantibodies (antinuclear antibody, antineutrophil cyto-
plasmic antibody, rheumatoid factor) and cryoglobulins were
negative, as well as for AFB in lymph. Direct Coombs, dosage
of complements, urinalysis and liver and renal functions were
within normal standards. High digestive endoscopy, chest
radiography, abdominal ultrasound, and Doppler for limbs
were normal. The echocardiogram showed no changes. Blood
and urine cultures showed no growth of microorganisms.
Biopsies of skin lesions were performed in the 2nd right ﬁnger
and pinna.
The diagnosis of relapsing polychondritis was proposed
based on the clinical manifestations found and on results
of complementary tests. In the light of these ﬁndings, a
treatment with prednisone 1 mg/kg/day was initiated. The
condition progressed to resolution of fever, conjunctival
lesions and joint conditions, but with no improvement of the
deafness and of ischemia in the 2nd chirodactyl after a week
of treatment. At that moment, it was decided to start pulse
therapy with methylprednisolone 1 g/day for three days.
The histopathology of the pinna showed the cartilage
with lymphocytic and neutrophilic inﬁltrate associated with
degeneration of hyaline matrix (Fig. 2). The histopathology of
cutaneous lesions of the right hand revealed necrosis with
extensive inﬁltration of neutrophils and lymphocytes.
After pulse therapy, the patient improved her skin con-
dition and with the disappearance of ischemic pain in her
2nd chirodactyl; however, a signiﬁcant loss of tissue by distal
necrosis had already taken place. Normalization of inﬂam-
matory markers (ESR 10 mm within 1 h; PCR, 5 mg/L) and
hemoglobin level (12 g/dL) was observed. Despite the com-
plete resolution of edema and pain in her pinnae, the patient
still remained with severe hearing loss. An otorhinolaryngo-
logical evaluation showed severe to profound sensorineural
bilateral hearing loss; thus, pulse therapy with cyclophos-
phamide was initiated. After six months of monthly therapy
with cyclophosphamide, the patient still remained with severe
bilateral hearing loss.
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Discussion
Patients with relapsing polychondritis exhibit a broad spec-
trum of clinical signs and symptoms that often increase the
diagnostic challenge. The diagnostic criteria have been pro-
posed by MacAdam, and require three or more  of the following
clinical features: bilateral auricular chondritis, seronegative
non-erosive polyarthritis, nasal chondritis, ocular inﬂam-
mation, respiratory tract chondritis and vestibulocochlear
dysfunction.4 A recent modiﬁcation of these criteria suggests
that the diagnosis can be made by the presence of at least
one of the MacAdam criteria, in association with histological
conﬁrmation of cartilage damage or chondritis in two dis-
tinct anatomical regions, with response to corticosteroids or
dapsone.5
The patient described had bilateral chondritis of the pinna,
bilateral conjunctivitis, seronegative non-erosive polyarthri-
tis, sensorineural hearing loss and compatible histopatholog-
ical ﬁndings, in compliance with criteria for the diagnosis of
RP. A pinna biopsy was performed, but the histopathology is
not always necessary to conﬁrm the diagnosis.
Early diagnosis is a difﬁcult task. Trentham and Le reported
that the average time to its establishment is of 2.9 years.6
The most frequent clinical manifestation is an unilateral or
bilateral inﬂammation of the ear cartilage, with an incidence
ranging from 43 to 83%. Arthritis is the second most common
manifestation. Around one third of cases occur in association
with other diseases such as systemic vasculitides, connec-
tive tissue diseases or myelodysplastic syndrome.2 In the case
reported, besides auricular chondritis and polyarthritis the
patient had severe sensorineural hearing loss and vasculitis-
compatible cutaneous manifestations.
Disorders of the inner ear occur in 40–50% of patients. Pro-
found hearing loss is rare.3,7 It was reported an association of
cutaneous vasculitis and severe hearing loss, but the patho-
genesis of this sensorineural injury is still uncertain. There
is a possibility of an obliterative vasculitis in the inner audi-
tory artery, causing otological injury.8,9 Another hypothesis,
raised by Issing et al., would be the presence of antilabyrinth
antibodies in the serum of patients with audiovestibular
dysfunction.10
Mucocutaneous manifestations occur in more  than 50% of
cases; aphthous ulcers are the most common change.2 A his-
tological evaluation of skin lesions has shown leukocytoclastic
vasculitis, neutrophilic inﬁltrates and thrombosis of skin ves-
sels more  often.11
Vasculitis is histologically observed in 14–25% of cases and
can be indolent or fulminant; additionally, it and can occur
simultaneously or independently of other manifestations.12
Drug treatment in patients with chondritis or arthritis
should be started with nonsteroidal anti-inﬂammatory drugs,
dapsone or corticosteroids. In those patients with severe man-
ifestations, systemic vasculitis or sensorineural hearing loss,
prednisone 1 mg/kg/day or pulse therapy with methylpred-
nisolone is the treatment of choice. In cases of resistance
to steroids, other immunosuppressive agents, including aza-
thioprine, methotrexate and cyclophosphamide, are reported
as being useful. Isolated case reports were published show-
ing potentially beneﬁcial results with antagonists of tumor 0 1 5;5 5(2):174–176
necrosis factor.2 In the case reported, prednisone 1 mg/kg/day
was started in a patient with a clinical picture compatible with
cutaneous vasculitis and severe injury in her inner ear. As the
condition has not evolved with the expected improvement of
its most severe manifestations, we  decided in favor of pulse
therapy with methylprednisolone and cyclophosphamide.
It is estimated that the ﬁve-year survival is 74%. Patients
younger than 51 years old and with systemic vasculitis have a
worse prognosis.13
Relapsing polychondritis is a multisystem disease with
variable presentation, which, in its spectrum of manifesta-
tions, can lead to serious and irreversible damage to target
organs. It is likely, that in the case reported, the permanence
of a severe hearing sequel, even with the institution of an
aggressive therapy, is explained by the long time elapsed
from the onset of clinical manifestations to the diagnosis and
institution of therapy. An early diagnosis, combined with an
aggressive therapy in cases of severe manifestations, can pro-
duce beneﬁcial effects in the prevention of serious sequelae.
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